The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The Europe medical cannabis market is expected to exhibit a CAGR of 22.8% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Medical cannabis, or medical marijuana, refers to the plant-derived psychotropic drugs used for the treatment of various medical ailments. It is usually sourced from cannabis indica, sativa and hybrid cannabis plants and the active ingredients include tetrahydrocannabinol (THC) and cannabidiol (CBD). Medical cannabis products are manufactured in the form of oils, capsules and other edible products. They are used for treating chronic pain, anxiety, anorexia, muscle spasms and nausea. Apart from this, they are also effective in modulating the immune system, promoting neuroplasticity and improving vascular and digestive functioning.
The increasing prevalence of chronic medical ailments, such as cancer, arthritis, Alzheimer’s and migraine, is one of the key factors creating a positive outlook for the market. Furthermore, the widespread adoption of medical cannabis for pain management is providing a thrust to the market growth. It is usually inhaled, smoked, orally administered or topically applied to numb the pain receptors and provide instant relief to the patients. Additionally, the legalization of medical cannabis in Europe has enhanced the accessibility of the products through healthcare centers and authorized dispensaries, thereby contributing to the market growth. Other factors, including, extensive research and development (R&D) activities for optimizing the use of cannabinoids, along with improvements in the healthcare infrastructure, are anticipated to drive the market further.
IMARC Group provides an analysis of the key trends in each sub-segment of the Europe medical cannabis market, along with forecasts at the regional and country level from 2022-2027. Our report has categorized the market based on species, derivative, application, end use and route of administration.
Breakup by Species:
Breakup by Derivative:
Breakup by Application:
Breakup by End Use:
Breakup by Route of Administration:
Breakup by Country:
The competitive landscape of the industry has also been examined along with the profiles of the key players.
|Base Year of the Analysis||2021|
|Segment Coverage||Species, Derivative, Application, End Use, Route of Administration, Country|
|Countries Covered||Germany, France, United Kingdom, Italy, Spain, Others|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2699
Five User License: US$ 3699
Corporate License: US$ 4699
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at